biote (BTMD) Expected to Announce Earnings on Wednesday

biote (NASDAQ:BTMD) will likely be issuing its Q4 2025 results after the market closes on Wednesday, March 11th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $45.79 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 5:00 PM ET.

biote Trading Up 0.5%

Shares of BTMD stock opened at $2.11 on Wednesday. The stock has a market cap of $96.34 million, a P/E ratio of 2.67 and a beta of 1.14. biote has a 1 year low of $2.02 and a 1 year high of $4.75. The stock has a 50 day simple moving average of $2.29 and a 200 day simple moving average of $2.70.

Analyst Upgrades and Downgrades

BTMD has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d+)” rating on shares of biote in a research report on Monday, December 29th. Truist Financial set a $5.00 target price on shares of biote in a report on Wednesday, January 7th. Finally, B. Riley Financial restated a “neutral” rating on shares of biote in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $5.67.

Institutional Investors Weigh In On biote

Several hedge funds and other institutional investors have recently made changes to their positions in BTMD. XTX Topco Ltd bought a new position in shares of biote in the 2nd quarter valued at $68,000. Occudo Quantitative Strategies LP bought a new stake in biote during the 3rd quarter worth $61,000. Franklin Resources Inc. acquired a new position in biote in the 3rd quarter worth about $58,000. Russell Investments Group Ltd. increased its holdings in biote by 209.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 18,663 shares of the company’s stock worth $56,000 after purchasing an additional 12,637 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in biote in the second quarter valued at about $53,000. 21.68% of the stock is owned by institutional investors.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.